☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update, Issue 5

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update Issue 5 (PDF).

This fifth issue includes the following drug safety advice articles:

  • Recombinant human erythropoietins: new prescribing advice
  • Rosiglitazone and pioglitazone: cardiovascular safety
  • Dosulepin: measures to reduce risk of fatal overdose
  • ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy
  • Short-acting β agonists: myocardial ischaemia

In addition, this issue contains hot topics focussing on potential side effects of varenicline and balancing of cardiovascular and gastrointestinal risks of NSAIDs. There is also a reminder to prescribers about the withdrawal of lumiracoxib and the risk of severe allergic reactions with strontium ranelate.

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update, Issue 5' by emailShare 'Drug Safety Update, Issue 5' on FacebookShare 'Drug Safety Update, Issue 5' on TwitterShare 'Drug Safety Update, Issue 5' on LinkedInShare 'Drug Safety Update, Issue 5' on reddit


No Comments to “Drug Safety Update, Issue 5”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.